Tetyana Yevsa
Hannover Medical School
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tetyana Yevsa.
Nature | 2011
Tae-Won Kang; Tetyana Yevsa; Norman Woller; Lisa Hoenicke; Torsten Wuestefeld; Daniel Dauch; Anja Hohmeyer; Marcus Gereke; Ramona Rudalska; Anna Potapova; Marcus Iken; Mihael Vucur; Siegfried Weiss; Mathias Heikenwalder; Sadaf Khan; Jesús Gil; Dunja Bruder; Michael P. Manns; Peter Schirmacher; Frank Tacke; Michael Ott; Tom Luedde; T Longerich; Stefan Kubicka; Lars Zender
Upon the aberrant activation of oncogenes, normal cells can enter the cellular senescence program, a state of stable cell-cycle arrest, which represents an important barrier against tumour development in vivo. Senescent cells communicate with their environment by secreting various cytokines and growth factors, and it was reported that this ‘secretory phenotype’ can have pro- as well as anti-tumorigenic effects. Here we show that oncogene-induced senescence occurs in otherwise normal murine hepatocytes in vivo. Pre-malignant senescent hepatocytes secrete chemo- and cytokines and are subject to immune-mediated clearance (designated as ‘senescence surveillance’), which depends on an intact CD4+ T-cell-mediated adaptive immune response. Impaired immune surveillance of pre-malignant senescent hepatocytes results in the development of murine hepatocellular carcinomas (HCCs), thus showing that senescence surveillance is important for tumour suppression in vivo. In accordance with these observations, ras-specific Th1 lymphocytes could be detected in mice, in which oncogene-induced senescence had been triggered by hepatic expression of NrasG12V. We also found that CD4+ T cells require monocytes/macrophages to execute the clearance of senescent hepatocytes. Our study indicates that senescence surveillance represents an important extrinsic component of the senescence anti-tumour barrier, and illustrates how the cellular senescence program is involved in tumour immune surveillance by mounting specific immune responses against antigens expressed in pre-malignant senescent cells.
Cell | 2013
Torsten Wuestefeld; Marina Pesic; Ramona Rudalska; Daniel Dauch; Thomas Longerich; Tae-Won Kang; Tetyana Yevsa; Florian Heinzmann; Lisa Hoenicke; Anja Hohmeyer; Anna Potapova; Ina Rittelmeier; Michael Jarek; Robert Geffers; Maren Scharfe; Frank Klawonn; Peter Schirmacher; Nisar P. Malek; Michael Ott; Alfred Nordheim; Arndt Vogel; Michael P. Manns; Lars Zender
The liver harbors a distinct capacity for endogenous regeneration; however, liver regeneration is often impaired in disease and therefore insufficient to compensate for the loss of hepatocytes and organ function. Here we describe a functional genetic approach for the identification of gene targets that can be exploited to increase the regenerative capacity of hepatocytes. Pools of small hairpin RNAs (shRNAs) were directly and stably delivered into mouse livers to screen for genes modulating liver regeneration. Our studies identify the dual-specific kinase MKK4 as a master regulator of liver regeneration. MKK4 silencing robustly increased the regenerative capacity of hepatocytes in mouse models of liver regeneration and acute and chronic liver failure. Mechanistically, induction of MKK7 and a JNK1-dependent activation of the AP1 transcription factor ATF2 and the Ets factor ELK1 are crucial for increased regeneration of hepatocytes with MKK4 silencing.
BMC Genomics | 2008
Roy Gross; Carlos A. Guzmán; Mohammed Sebaihia; Vitor A. P. Martins dos Santos; Dietmar H. Pieper; Ralf Koebnik; Melanie Lechner; Daniela Bartels; Jens Buhrmester; Jomuna V. Choudhuri; Thomas Ebensen; Lars Gaigalat; Stefanie Herrmann; Amit N. Khachane; Christof Larisch; Stefanie Link; Burkhard Linke; Folker Meyer; Sascha Mormann; Diana Nakunst; Christian Rückert; Susanne Schneiker-Bekel; Kai Schulze; Frank-Jörg Vorhölter; Tetyana Yevsa; Jacquelyn T. Engle; William E. Goldman; Alfred Pühler; Ulf B. Göbel; Alexander Goesmann
BackgroundBordetella petrii is the only environmental species hitherto found among the otherwise host-restricted and pathogenic members of the genus Bordetella. Phylogenetically, it connects the pathogenic Bordetellae and environmental bacteria of the genera Achromobacter and Alcaligenes, which are opportunistic pathogens. B. petrii strains have been isolated from very different environmental niches, including river sediment, polluted soil, marine sponges and a grass root. Recently, clinical isolates associated with bone degenerative disease or cystic fibrosis have also been described.ResultsIn this manuscript we present the results of the analysis of the completely annotated genome sequence of the B. petrii strain DSMZ12804. B. petrii has a mosaic genome of 5,287,950 bp harboring numerous mobile genetic elements, including seven large genomic islands. Four of them are highly related to the clc element of Pseudomonas knackmussii B13, which encodes genes involved in the degradation of aromatics. Though being an environmental isolate, the sequenced B. petrii strain also encodes proteins related to virulence factors of the pathogenic Bordetellae, including the filamentous hemagglutinin, which is a major colonization factor of B. pertussis, and the master virulence regulator BvgAS. However, it lacks all known toxins of the pathogenic Bordetellae.ConclusionThe genomic analysis suggests that B. petrii represents an evolutionary link between free-living environmental bacteria and the host-restricted obligate pathogenic Bordetellae. Its remarkable metabolic versatility may enable B. petrii to thrive in very different ecological niches.
Nature Medicine | 2016
Daniel Dauch; Ramona Rudalska; Giacomo Cossa; Jean-Charles Nault; Tae-Won Kang; Torsten Wuestefeld; Anja Hohmeyer; Sandrine Imbeaud; Tetyana Yevsa; Lisa Hoenicke; Tatu Pantsar; Przemyslaw Bozko; Nisar P. Malek; Thomas Longerich; Stefan Laufer; Antti Poso; Jessica Zucman-Rossi; Martin Eilers; Lars Zender
MYC oncoproteins are involved in the genesis and maintenance of the majority of human tumors but are considered undruggable. By using a direct in vivo shRNA screen, we show that liver cancer cells that have mutations in the gene encoding the tumor suppressor protein p53 (Trp53 in mice and TP53 in humans) and that are driven by the oncoprotein NRAS become addicted to MYC stabilization via a mechanism mediated by aurora kinase A (AURKA). This MYC stabilization enables the tumor cells to overcome a latent G2/M cell cycle arrest that is mediated by AURKA and the tumor suppressor protein p19ARF. MYC directly binds to AURKA, and inhibition of this protein–protein interaction by conformation-changing AURKA inhibitors results in subsequent MYC degradation and cell death. These conformation-changing AURKA inhibitors, with one of them currently being tested in early clinical trials, suppressed tumor growth and prolonged survival in mice bearing Trp53-deficient, NRAS-driven MYC-expressing hepatocellular carcinomas (HCCs). TP53-mutated human HCCs revealed increased AURKA expression and a positive correlation between AURKA and MYC expression. In xenograft models, mice bearing TP53-mutated or TP53-deleted human HCCs were hypersensitive to treatment with conformation-changing AURKA inhibitors, thus suggesting a therapeutic strategy for this subgroup of human HCCs.
Arthritis & Rheumatism | 2016
Annika Reinhardt; Tetyana Yevsa; Tim Worbs; Stefan Lienenklaus; Inga Sandrock; Linda Oberdörfer; Thomas Korn; Siegfried Weiss; Reinhold Förster; Immo Prinz
The spondyloarthritides (SpA) are a group of rheumatic diseases characterized by ossification and inflammation of entheseal tissue, the region where tendon attaches to bone. Interleukin‐23 (IL‐23) is involved in the pathogenesis of SpA by acting on IL‐23 receptor (IL‐23R) expressed on enthesis‐resident lymphocytes. Upon IL‐23 binding, CD3+CD4−CD8− tissue‐resident lymphocytes secrete IL‐17A and IL‐22, leading to inflammation, bone loss, and ossification. Knowledge about enthesis‐resident lymphocytes remains fragmentary, and the contribution of entheseal γ/δ T cells in particular is not clear. This study was undertaken to investigate the presence of γ/δ T cells in the enthesis.
Vaccine | 2008
Angel Cataldi; Tetyana Yevsa; Daniel A. Vilte; Kai Schulze; M. Castro-Parodi; Mariano Larzábal; Cristina Ibarra; Elsa C. Mercado; Carlos A. Guzmán
Mucosal vaccine formulations based on purified recombinant C280 gamma-Intimin and EspB (Escherichia coli secreted protein B) from enterohaemorragic E. coli co-administered with a pegylated derivative of the TLR2/6 agonist MALP-2 (macrophage-activating lipopeptide) as adjuvant were evaluated in BALB/c mice. After intranasal vaccination, strong humoral and cellular immune responses were observed against C280 gamma-Intimin and EspB. Sera of immunized mice inhibit bacterial haemolytic activity in vitro. Antigen-specific T-cell proliferation, IL-4, IL-2 and IFN-gamma producing cells, and secretory IgA were mostly detected in animals receiving MALP-2 as adjuvant. These results suggest that C280 gamma-Intimin and EspB are good candidate antigens to be incorporated into mucosal vaccines against this important pathogen.
Arthritis & Rheumatism | 2016
Annika Reinhardt; Tetyana Yevsa; Tim Worbs; Stefan Lienenklaus; Inga Sandrock; Linda Oberdörfer; Thomas Korn; Siegfried Weiss; Reinhold Förster; Immo Prinz
The spondyloarthritides (SpA) are a group of rheumatic diseases characterized by ossification and inflammation of entheseal tissue, the region where tendon attaches to bone. Interleukin‐23 (IL‐23) is involved in the pathogenesis of SpA by acting on IL‐23 receptor (IL‐23R) expressed on enthesis‐resident lymphocytes. Upon IL‐23 binding, CD3+CD4−CD8− tissue‐resident lymphocytes secrete IL‐17A and IL‐22, leading to inflammation, bone loss, and ossification. Knowledge about enthesis‐resident lymphocytes remains fragmentary, and the contribution of entheseal γ/δ T cells in particular is not clear. This study was undertaken to investigate the presence of γ/δ T cells in the enthesis.
OncoImmunology | 2012
Tetyana Yevsa; Tae-Won Kang; Lars Zender
Here we discuss a recently published study from our group on how a continuous CD4 T-cell dependent immune clearance of premalignant senescent cells, designated “senescence surveillance,” restricts liver cancer development.
Environmental Microbiology | 2013
Tetyana Yevsa; Thomas Ebensen; Barbara Fuchs; Beata M. Zygmunt; Rimma Libanova; Roy Gross; Kai Schulze; Carlos A. Guzmán
Bordetella bronchiseptica is an important pathogen causing a number of veterinary respiratory syndromes in agriculturally important and food-producing confinement-reared animals, resulting in great economic losses annually amounting to billions of euros worldwide. Currently available live vaccines are incompletely satisfactory in terms of efficacy and safety. An efficient vaccine for livestock animals would allow reducing the application of antibiotics, thereby preventing the massive release of pharmaceuticals into the environment. Here, we describe two new potential vaccine strains based on the BB7865 strain. Two independent attenuating mutations were incorporated by homologous recombination in order to make negligible the risk of recombination and subsequent reversion to the virulent phenotype. The mutations are critical for bacterial metabolism, resistance to oxidative stress, intracellular survival and in vivo persistence. The resulting double mutants BB7865 risA aroA and BB7865 risA dapE were characterized as promising vaccine candidates, which are able to confer protection against colonization of the lower respiratory tract after sublethal challenge with the wild-type strain.
Human Vaccines & Immunotherapeutics | 2017
Inga Hochnadel; Uta Kossatz-Boehlert; Nils Jedicke; Henrike Lenzen; Michael P. Manns; Tetyana Yevsa
ABSTRACT Hepatobiliary and pancreatic cancers along with other gastrointestinal malignancies remain the leading cause of cancer-related deaths worldwide. Strategies developed in the recent years on immunotherapy and cancer vaccines in the setting of primary liver cancer as well as in pancreatic cancer are the scope of this review. Significance of orthotopic and autochthonous animal models which mimic and/or closely reflect human malignancies allowing for a prompt and trustworthy analysis of new therapeutics is underlined. Combinational approaches that on one hand, specifically target a defined cancer-driving pathway, and on the other hand, restore the functions of immune cells, which effector functions are often suppressed by a tumor milieu, are shown to have the strongest perspectives and future directions. Among combinational immunotherapeutic approaches a personalized- and individual cancer case-based therapy is of special importance.